These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 28302396)
21. Preparation of sustained release rifampicin microparticles for inhalation. Son YJ; McConville JT J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441 [TBL] [Abstract][Full Text] [Related]
22. Supercritical fluid assisted atomization introduced by an enhanced mixer for micronization of lysozyme: Particle morphology, size and protein stability. Du Z; Guan YX; Yao SJ; Zhu ZQ Int J Pharm; 2011 Dec; 421(2):258-68. PubMed ID: 22001535 [TBL] [Abstract][Full Text] [Related]
23. Characterization of polymeric dispersions of dimenhydrinate in ethyl cellulose for controlled release. Desai J; Alexander K; Riga A Int J Pharm; 2006 Feb; 308(1-2):115-23. PubMed ID: 16326055 [TBL] [Abstract][Full Text] [Related]
24. Preparation, characterization and in vivo assessment of the bioavailability of glycyrrhizic acid microparticles by supercritical anti-solvent process. Sui X; Wei W; Yang L; Zu Y; Zhao C; Zhang L; Yang F; Zhang Z Int J Pharm; 2012 Feb; 423(2):471-9. PubMed ID: 22183131 [TBL] [Abstract][Full Text] [Related]
25. Novel rifampicin-phospholipid complex for tubercular therapy: synthesis, physicochemical characterization and in-vivo evaluation. Singh C; Bhatt TD; Gill MS; Suresh S Int J Pharm; 2014 Jan; 460(1-2):220-7. PubMed ID: 24188983 [TBL] [Abstract][Full Text] [Related]
26. Comparative physicochemical characterization of phospholipids complex of puerarin formulated by conventional and supercritical methods. Li Y; Yang DJ; Chen SL; Chen SB; Chan AS Pharm Res; 2008 Mar; 25(3):563-77. PubMed ID: 17828444 [TBL] [Abstract][Full Text] [Related]
27. Modified supercritical antisolvent method with enhanced mass transfer to fabricate drug nanoparticles. Kakran M; Sahoo NG; Antipina MN; Li L Mater Sci Eng C Mater Biol Appl; 2013 Jul; 33(5):2864-70. PubMed ID: 23623107 [TBL] [Abstract][Full Text] [Related]
28. Preparation and physicochemical properties of vinblastine microparticles by supercritical antisolvent process. Zhang X; Zhao X; Zu Y; Chen X; Lu Q; Ma Y; Yang L Int J Mol Sci; 2012 Oct; 13(10):12598-607. PubMed ID: 23202916 [TBL] [Abstract][Full Text] [Related]
29. [Preparation of curcumin-EC sustained-release composite particles by supercritical CO2 anti-solvent technology]. Bai WL; Yan TY; Wang ZX; Huang DC; Yan TX; Li P Zhongguo Zhong Yao Za Zhi; 2015 Jan; 40(2):226-30. PubMed ID: 26080549 [TBL] [Abstract][Full Text] [Related]
30. [Preparation of ibuprofen/EC-PVP sustained-release composite particles by supercritical CO2 anti-solvent technology]. Cai JY; Huang DC; Wang ZX; Dang BL; Wang QL; Su XG Yao Xue Xue Bao; 2012 Jun; 47(6):791-6. PubMed ID: 22919729 [TBL] [Abstract][Full Text] [Related]
31. Supercritical antisolvent precipitation of nimesulide: preliminary experiments. Moneghini M; Perissutti B; Vecchione F; Kikic I; Alessi P; Cortesi A; Princivalle F Curr Drug Deliv; 2007 Jul; 4(3):241-8. PubMed ID: 17627498 [TBL] [Abstract][Full Text] [Related]
32. Rehydrated lyophilized rifampicin-loaded mPEG-DSPE formulations for nebulization. Abdulla JM; Tan YT; Darwis Y AAPS PharmSciTech; 2010 Jun; 11(2):663-71. PubMed ID: 20405256 [TBL] [Abstract][Full Text] [Related]
33. Morphological and Physicochemical Evaluation of Two Distinct Glibenclamide/Hypromellose Amorphous Nanoparticles Prepared by the Antisolvent Method. Yonashiro H; Higashi K; Morikawa C; Ueda K; Itoh T; Ito M; Masu H; Noguchi S; Moribe K Mol Pharm; 2018 Apr; 15(4):1587-1597. PubMed ID: 29502422 [TBL] [Abstract][Full Text] [Related]
34. Supercritical antisolvent precipitation of PHBV microparticles. Costa MS; Duarte AR; Cardoso MM; Duarte CM Int J Pharm; 2007 Jan; 328(1):72-7. PubMed ID: 16971075 [TBL] [Abstract][Full Text] [Related]
35. Preparation and pharmaceutical characterization of amorphous cefdinir using spray-drying and SAS-process. Park J; Park HJ; Cho W; Cha KH; Kang YS; Hwang SJ Int J Pharm; 2010 Aug; 396(1-2):239-45. PubMed ID: 20599602 [TBL] [Abstract][Full Text] [Related]
36. Preparation and in vitro evaluation of ethyl cellulose microspheres containing stavudine by the double emulsion method. Sahoo SK; Mallick AA; Barik BB; Senapati PC Pharmazie; 2007 Feb; 62(2):117-21. PubMed ID: 17341031 [TBL] [Abstract][Full Text] [Related]
37. The relevancy of controlled nanocrystallization on rifampicin characteristics and cytotoxicity. Mohyeldin SM; Mehanna MM; Elgindy NA Int J Nanomedicine; 2016; 11():2209-22. PubMed ID: 27274244 [TBL] [Abstract][Full Text] [Related]
38. Nanosized bicalutamide and its molecular structure in solvents. Le Y; Ji H; Chen JF; Shen Z; Yun J; Pu M Int J Pharm; 2009 Mar; 370(1-2):175-80. PubMed ID: 19101616 [TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process. Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129 [TBL] [Abstract][Full Text] [Related]
40. In Situ Monitoring and Modeling of the Solution-Mediated Polymorphic Transformation of Rifampicin: From Form II to Form I. Guo N; Hou B; Wang N; Xiao Y; Huang J; Guo Y; Zong S; Hao H J Pharm Sci; 2018 Jan; 107(1):344-352. PubMed ID: 29031974 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]